Profil
Josh Spiegel is currently the President at NetraMark Corp.
He completed his undergraduate degree at Duke University.
Postes actifs de Josh Spiegel
| Sociétés | Poste | Début |
|---|---|---|
NetraMark Corp.
 NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | President | 14/07/2022 |
Formation de Josh Spiegel
| Duke University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
NetraMark Corp.
NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Technology Services |
